Physician-assisted suicide and physician-assisted euthanasia: evidence from abroad and implications for UK neurologists.

dementia depression evidence-based neurology health policy & practice neuroepidemiology

Journal

Practical neurology
ISSN: 1474-7766
Titre abrégé: Pract Neurol
Pays: England
ID NLM: 101130961

Informations de publication

Date de publication:
Jun 2021
Historique:
accepted: 15 02 2021
pubmed: 15 4 2021
medline: 19 11 2021
entrez: 14 4 2021
Statut: ppublish

Résumé

In this article, we consider the arguments for and against physician-assisted suicide (AS) and physician-assisted euthanasia (Eu). We assess the evidence around law and practice in three jurisdictions where one or both are legal, with emphasis on data from Oregon. We compare the eligibility criteria in these different regions and review the range of approved disorders. Cancer is the most common cause for which requests are granted, with neurodegenerative diseases, mostly motor neurone disease, ranking second. We review the issues that may drive requests for a physician-assisted death, such as concerns around loss of autonomy and the possible role of depression. We also review the effectiveness and tolerability of some of the life-ending medications used. We highlight significant variation in regulatory oversight across the different models. A large amount of data are missing or unavailable. We explore physician-AS and physician-assisted Eu within the wider context of end-of-life practice.

Identifiants

pubmed: 33850034
pii: practneurol-2020-002811
doi: 10.1136/practneurol-2020-002811
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

205-211

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: CR and ML are the members of the Association of Palliative Medicine. CR manages the KADOH website (www.kadoh.uk).

Auteurs

Uma Nath (U)

Neurology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, Tyne and Wear, UK uma.nath@chsft.nhs.uk.

Claud Regnard (C)

Palliative Medicine, St Oswald's Hospice, Newcastle upon Tyne, UK.

Mark Lee (M)

Palliative Medicine, St Benedict's Hospice, South Tyneside and Sunderland NHS Trust, Sunderland, UK.

Kiran Alexander Lloyd (KA)

Department of Philosophy, Oxford University, Oxford, Oxfordshire, UK.

Louise Wiblin (L)

Neurology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH